Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy in relapsed/refractory follicular lymphoma
2017-001552-54Phase 2Active
- Sponsor
- BeiGene
- Start
- Oct 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in follicular lymphoma (FL) comparing Zanubrutinib + obinutuzumab with Obinutuzumab monotherapy (2 arms). Primary endpoint: Overall response rate by independent central review. Started Oct 2017; status: active.
02
Drugs
zanubrutinibobinutuzumab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2017-001552-54.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001552-54.